


In re: James Duncan Morrison et al.  
Serial No. to be assigned  
Filed: concurrently herewith  
Page 4

**REMARKS**

The above amendment to the specification has been made to claim priority to the identified PCT and British patent applications. The above claims have been amended to better conform to U.S. practice. Applicants respectfully request substantive examination on the merits.

Respectfully submitted,

  
F. Michael Sajovec  
Registration No. 31,793



20792


PATENT TRADEMARK OFFICE

**CERTIFICATE OF EXPRESS MAILING**

Express Mail Label No. EL920741553US

Date of Deposit: March 21, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PCT, Attn: DO/EO/US, Commissioner for Patents, Washington, DC 20231.

  
Lucille H. Gillette

In re: James Duncan Morrison et al.  
Serial No. to be assigned  
Filed: concurrently herewith  
Page 5

**"Version with Marking to Show Changes Made"**

3. (Amended) The amide according to **[either of claims 1 or 2]** claim 1 wherein the peptide is from 4 to 600 amino acids long.

5. (Amended) The amide according to **[any preceding]** claim 1 wherein the bile salt is mono-, di- or tri-hydroxylated.

6. (Amended) The amide according to **[any preceding]** claim 1 wherein the bile salt contains a 3 $\alpha$ -hydroxyl group.

7. (Amended) The amide according to **[any previous]** claim 1 wherein the bile salt is an amphiphilic polyhydric sterol bearing carboxyl groups as part of the primary side chain.

8. (Amended) The amide according to **[any previous]** claim 1 wherein the bile salt is underivatised or derivatised.

12. (Amended) An amide according to **[any previous]** claim 1 wherein the peptide is selected from insulin, secretin, gastrin, gastrin releasing peptide, glucagon, cholecystokinin (CCK) gastric inhibitory peptide (also known as glucose insulinotropic peptide (GIP)), parathyroid hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone (also known as lutenizing hormone releasing hormone (LHRH)), corticotropin-releasing hormone, somatostatin, adrencorticotropic hormone (ACTH), renin, angiotensin I, angiotensin II, atrial natriuretic hormone (ANH), somatomedins, calcitonin, haemoglobin, cytochrome C, horseradish peroxidase, aprotinin, muchroom tyrosinase, erythropoietin, somatotropin (growth hormone), growth hormone releasing hormone, galanin, urokinase, Factor IX (also known as Christmas factor), tissue plasminogen activator, antibodies superoxide dismutase, catalase, peroxidase, ferritin, interferon, Factor VIII, soy bean trypsin inhibitor, GLP1, blood coagulation factors, somatostatin, antidiuretic hormone (ADH),

In re: James Duncan Morrison et al.  
Serial No. to be assigned  
Filed: concurrently herewith  
Page 6

oxytocin, polysaccharides, hirudin, and glycoproteins, such as follicle stimulating hormone (FSH), lutenizing hormone (LH) inhibin, chorionic gonadotropin (CGT) and thyroid stimulating hormone (TSH), and analogues and fragments of all these, or mixtures of one or more of these.

15. (Amended) A pharmaceutical formulation, comprising an amide according to **[any preceding]** claim 1 and a pharmaceutically acceptable carrier.

18. (Amended) An amide according to **[any one of claims 1-14]** claim 1 or a physiologically functional derivative thereof, for use in therapy.

19. (Amended) A method for the preparation of a pharmaceutical formulation comprising bringing into association an amide according to **[any one of claims 1-14]** claim 1 and a pharmaceutically acceptable carrier thereof.

20. (Amended) Use of an amide according to **[any one of claims 1-14]** claim 1 in the manufacture of a medicament in a form suitable for oral administration.

23. (Amended) Use according to **[to claim 21 or]** claim 1 wherein said pharmaceutical agent is selected from polypeptides and glycoproteins, polysaccharides, oligonucleotides/polynucleotides, anaesthetics, anxiolytics, hypotics, neuroleptics, anti-depressants, anti-epileptics, anti-Parkinsonian drugs, opioid analgesics, neuropeptide transmitters, neuropeptide transmitter antagonists, muscarinic agonists, anti-cholinesterases, muscarinic antagonists, nicotinic antagonists, direct sympathomimetics, indirect sympathomimetics, adrenergic blocking drugs, adrenoceptor antagonists, vasodilators, anti-angina drugs, cardiogenic drugs, anti-dysrhythmic drugs, anti-coagulants, plasma lipid lowering drugs, anti-anaemia drugs, anti-inflammatory drugs, diuretics, histamine antagonists, anti-peptic ulcer drugs, anti-gut motility disorder drugs, chemotherapy drugs, anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs.